A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q54681050

about

Optimal combination of antiangiogenic therapy for hepatocellular carcinoma Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy Structural Insights into the Functions of TBK1 in Innate Antimicrobial Immunity Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma FGFR1 amplifications in squamous cell carcinomas of the lung: diagnostic and therapeutic implications.Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.HCC and angiogenesis: possible targets and future directions A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.Antiangiogenic therapies for advanced hepatocellular carcinoma.Targeted therapies for hepatocellular carcinoma.Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer Clinical trials in hepatocellular carcinoma: an update.Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy.Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.The molecular pathogenesis and clinical implications of hepatocellular carcinoma.Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.FGF receptor inhibitors: role in cancer therapy.Targeted therapy of hepatocellular carcinoma: present and future.Management of hepatocellular carcinoma: beyond sorafenib.Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages.Impact of restricting access to high-cost medications for hepatocellular carcinoma.Pathways and targets in hepatocellular carcinoma.New agents on the horizon in hepatocellular carcinoma.Molecular targeted therapy for hepatocellular carcinoma: current and future.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.Fibroblast growth factor signaling in liver carcinogenesis.New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.Targeting the tumor stroma in hepatocellular carcinoma.Multi-kinase inhibitors, AURKs and cancer.Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma.Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.Polymorphisms of FGFR1 in HBV-related hepatocellular carcinoma.Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.Anti-angiogenesis in hepatocellular carcinoma treatment: current evidence and future perspectives.Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial.

P2860

Q26799458-98F8475E-C48D-4336-A4AD-C04F5C216FD8 Q27005850-696E2405-F7BE-42FA-ADCD-AC3534D86014 Q27678533-5E4E4248-57D3-4C26-8A43-27D677108DC3 Q34217671-8E691D20-ED89-46AA-93DB-B934F346EA67 Q35206634-A9ACB174-98BE-4B50-BDF0-C524BB360A8A Q35501246-47F4F2CE-F519-44EE-9B97-DC1126D2261D Q35698574-A3E34FE8-F3E9-42FC-8411-D813CC9716A3 Q36223538-1D4A0222-3A01-443A-B7BB-2AD37D6D302B Q36382891-9DBF1A06-3AC0-42D4-9225-B4520BA8C68D Q36644408-660F17FD-CD74-4D51-B81F-53D4F921DB2D Q36804518-10B9EA04-F927-4572-8977-022FF243096C Q36928888-CE054766-9C05-4EDB-88FA-43ACCA43A2E2 Q37235534-36BD5453-4722-4E89-8FC5-4E2E8C353B09 Q37435638-CA0ACF78-EE46-4868-B878-C38F74F70011 Q37635310-C395D7B4-0E0A-4D38-99C0-6CE197E5C697 Q37914633-ADAB9AF2-F2B7-47E6-B828-A34D23656057 Q37970351-0B8D4A74-BE16-4968-A379-8D9DC7CB6876 Q37978104-9BF20C0A-04DB-4F03-B522-66034F7A32B5 Q37981986-45A17A0E-FB9C-4F32-982A-45FEC2C73734 Q37988604-4345C0CA-0C17-4A82-BF9C-E1FC6290D572 Q37995523-0446391F-AF55-4923-A926-E569C3189CF9 Q37996468-B473F515-EB90-4EAA-9BB0-C2AC30495834 Q38042711-A36D051D-414B-4CF7-AF81-7712FC562BBB Q38062022-708A43BF-FDB0-44B3-9F40-78315F428BDD Q38074429-35153291-FC97-411B-90C6-0049AF729BC4 Q38151670-DD05FB12-3F1B-4D5C-854B-C8541C2AFF18 Q38160838-81C0209F-444D-450A-9F23-1336EE4F7D18 Q38184582-F782C0D4-CBF8-4729-BCBD-3855881452D2 Q38203285-5120B81F-7B0C-4631-8842-0A983F4D10EA Q38282800-24897080-197A-4DC9-9301-86D2DD1EB8C2 Q38354294-46D102DE-E6CB-4651-8000-53F2221915A0 Q38366586-E1862ADE-1C83-4403-83AA-7358F2D4F257 Q38796360-8020E734-ED44-4C7C-B8D9-2CDDEBD2CCC3 Q38923517-AE1BFA99-E6B5-46C3-9A51-6F66F2210CA8 Q40707153-9DCC0D44-5B44-4896-95B5-575D0483B529 Q41166121-46EED969-4AFD-40C3-B610-AE57F6C7BFA1 Q41761530-57B747CF-D30E-4AA2-89C9-EDE9BF4429B9 Q42053469-31CDE880-786C-428B-B41D-53C320E9D3D0 Q42871162-5DEB8F27-9F70-4C30-A77A-D466AE3B0BB5 Q53287385-CE85DE08-9F15-4EEA-AC0B-3AC6C5C548FF

P2860

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q54681050

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

A phase I/II trial of the oral ...... nced hepatocellular carcinoma.

@en

A phase I/II trial of the oral ...... nced hepatocellular carcinoma.

@nl

type

label

A phase I/II trial of the oral ...... nced hepatocellular carcinoma.

@en

A phase I/II trial of the oral ...... nced hepatocellular carcinoma.

@nl

prefLabel

A phase I/II trial of the oral ...... nced hepatocellular carcinoma.

@en

A phase I/II trial of the oral ...... nced hepatocellular carcinoma.

@nl

P1433

Q54681050-04971DEC-D135-4EE6-B1F2-58D6F6DF407B

P1476

Q54681050-74B9D966-94E8-4C25-BAEC-02D1CF0DDEF6

P2093

Q54681050-0BFA8831-28B2-4B58-82FC-5DA082F97F62

Q54681050-0DC6FF83-EC94-4A9E-80F8-D767EE042352

Q54681050-31FCBF33-4160-4416-9DC6-B1E400306B90

Q54681050-4F71C36F-A9DA-4625-9AEF-9BADDE4A5DA3

Q54681050-6E681DC8-0939-40A3-8F80-3BF61C10567B

Q54681050-8671CE60-81A4-4A92-913F-8B17F32411ED

Q54681050-8A2348E1-8E08-4C63-A78F-6B90825C3555

Q54681050-8A6EE0A1-800A-4E72-88DA-35F791020F09

Q54681050-AAB55EEB-4293-44C8-B001-2D308F480561

Q54681050-C40D5043-732F-46D0-A8A6-C6BED74AFBDF

P2860

Q54681050-1D88B75E-6BCC-44AE-BFCE-AEACEE3A66C6

Q54681050-24CD5D17-9656-4770-9E70-A77DA73184FB

Q54681050-24F55BDD-2A19-4AFE-BB61-D2F7D2939F34

Q54681050-309AF350-DD2F-4EB3-ABCE-000AEDB80258

Q54681050-32F7E4B0-2756-49FB-8FF8-8C0A0EF87DDB

Q54681050-3BE888ED-12BB-42D5-89FA-1ADFC10DA5CF

Q54681050-4586D351-7296-4D12-81A8-B23AFC46EA2F

Q54681050-600D99D0-37DE-4793-86C0-A2663721F8EC

Q54681050-62D6427B-96F6-42E2-A198-4EBEB1601BB9

Q54681050-A92DA4FD-E52B-46EE-9381-C2251482851F

P2888

Q54681050-68E38486-749B-446F-B92B-E208787347A3

P304

Q54681050-BE523C22-0BD1-44EE-886C-9FAC18ABA078

P31

Q54681050-17570B66-0DE4-444F-84E9-BE75CDD6A9D2

P356

Q54681050-77661FD9-1944-453E-8010-A2091983C23A

P433

Q54681050-F2E050D4-8A48-4539-B66E-A24214CACC3F

P478

Q54681050-881D3739-9412-4AD7-A3C3-3F63AFFA24F8

P50

Q54681050-9E1AACC5-DE36-4986-99D9-5CF2C4595CD4

P577

Q54681050-986FE700-3B08-445E-A12D-D5EF6D5F1C92

P698

Q54681050-C57FE0DB-DC79-400E-8C35-B18921811FD6

P921

Q54681050-25B31868-B204-42C8-BEBD-FAE5AB1ECC08

Q54681050-9DCC7D7C-458C-4054-BCB2-EFC51A12FAEF

Q54681050-FD358403-F7AE-4C63-92F9-6D9D5DCB01A0

P356

S00280-010-1320-2

P1433

Cancer Chemotherapy and Pharmacology

P1476

A phase I/II trial of the oral ...... nced hepatocellular carcinoma.

@en

P2093

Chigusa Morizane

http://www.w3.org/2001/XMLSchema#string

Fumihiko Kanai

http://www.w3.org/2001/XMLSchema#string

Haruhiko Yoshida

http://www.w3.org/2001/XMLSchema#string

Hitoshi Arioka

http://www.w3.org/2001/XMLSchema#string

Kazumi Tagawa

http://www.w3.org/2001/XMLSchema#string

Makoto Taniguchi

http://www.w3.org/2001/XMLSchema#string

Masafumi Ikeda

http://www.w3.org/2001/XMLSchema#string

Masao Omata

http://www.w3.org/2001/XMLSchema#string

Shinpei Sato

http://www.w3.org/2001/XMLSchema#string

Shuichiro Shiina

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Management of hepatocellular carcinoma

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

Novel advancements in the management of hepatocellular carcinoma in 2008.

Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma.

Opportunities for targeted therapies in hepatocellular carcinoma.

Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.

P2888

s00280-010-1320-2

P304

315-324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-010-1320-2

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Ryosuke Tateishi

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20390419

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial